Platinum-based chemotherapeutics are widely used for cancer treatment but are frequently
limited because of dosage-dependent side effects and drug resistance. To attenuate these …

Developing multitarget platinum (IV) prodrugs is an important strategy to attenuate cisplatin
(CDDP) resistance in tandem with reduced toxicity. Herein, six novel ligustrazine-derived …

The development and optimization of metal-based anticancer drugs with novel cytotoxic
mechanisms have emerged as key strategies to overcome chemotherapeutic resistance and …

Developing multifunctional platinum (IV) prodrugs via integrating bioactive pharmacophores
into one entity is an attractive strategy to ameliorate the defects of platinum (II) drugs. Herein …

Despite phenomenal clinical success, the efficacy of platinum anticancer drugs is often
compromised due to inherent and acquired drug resistant phenotypes in cancers. To …

As a platinum-containing anticancer drug, cisplatin is the keystone for treating many
malignancies. Nephrotoxicity is the main dose-limiting toxicity, and several hydration …

Ferroptosis, characterized by iron‐dependent lipid reactive oxygen species (ROS)
accumulation, plays a pivotal role in cisplatin‐induced ototoxicity. Existing research has …

In order to develop a novel platinum (Pt) complex aiming to overcome cisplatin resistance,
we synthesised a series of novel Pt complexes (C1–C6). These Pt complexes displayed …

The efficacy and resistance of cisplatin-based compounds are very intractable problems at
present. This study reports a series of platinum (IV) compounds containing multiple-bond …

Oxaliplatin-based chemotherapy is the current standard of care in adjuvant therapy for
advanced colorectal cancer (CRC). But acquired resistance to oxaliplatin eventually occurs …